Pulmonx Corporation
Moat Score — Pulmonx Corporation
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 | Zephyr Valve and Chartis diagnostic system are protected by patents and extensive clinical trial data supporting FDA approval and payer reimbursement, which is difficult for a new entrant to replicate quickly. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 | As a sub-$100 million revenue company, Pulmonx lacks meaningful manufacturing scale cost advantages versus larger device makers, though its high gross margin (73-74%) reflects strong unit economics on a small base. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 | High, stable gross margins near 74% despite being a single-product-platform company indicate real pricing power within its clinical niche, supported by reimbursement coverage. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 | The Zephyr Valve procedure carries no network effect; value to one patient or physician does not increase as more procedures are performed elsewhere. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 | Once hospitals invest in Chartis diagnostic equipment and train physicians on the bronchoscopic procedure, switching to an alternative therapy requires significant retraining and new capital equipment. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 | The severe-emphysema bronchoscopic valve market is a relatively narrow clinical niche that does not obviously support more than a small number of well-capitalized competitors, but it is not yet proven to be a hard scale barrier. |
| Total Moat Score | — | |
| Maximum Score | — |